Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D00251 Captopril [8] 6, 17, 46, 86, 96, 97, 107, 271
2 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D00362 Lisinopril [7] 19, 46, 49, 66, 67, 113, 222
3 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D00421 Ramipril [7] 46, 49, 66, 67, 113, 218, 257
4 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D00459 Quinapril [1] 19
5 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D00620 Benazepril [4] 49, 57, 218, 224
6 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D00621 Enalapril [6] 19, 46, 66, 113, 210, 222
7 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D00623 Moexipril [1] 93
8 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D00624 Perindopril [4] 58, 113, 167, 222
9 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D01069 Cilazapril [1] 66
10 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D03752 Quinapril [1] 19
11 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D03753 Perindopril [4] 58, 113, 167, 222
12 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D07499 Benazepril [4] 49, 57, 218, 224
13 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D07699 Cilazapril [1] 66
14 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D07892 Enalapril [6] 19, 46, 66, 113, 210, 222
15 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D08068 Imidapril [1] 67
16 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D08131 Lisinopril [7] 19, 46, 49, 66, 67, 113, 222
17 ACE [3] Renin-angiotensin system, Renin secretion, Hypertrophic cardiomyopathy D08225 Moexipril [1] 93
18 DMD [2] Hypertrophic cardiomyopathy, Viral myocarditis D09900 Eteplirsen [1] 113
19 DMD [2] Hypertrophic cardiomyopathy, Viral myocarditis D10114 Drisapersen [1] 113
20 DMD [2] Hypertrophic cardiomyopathy, Viral myocarditis D11528 Viltolarsen [1] 113
21 DMD [2] Hypertrophic cardiomyopathy, Viral myocarditis D11707 Golodirsen [1] 113
22 DMD [2] Hypertrophic cardiomyopathy, Viral myocarditis D11988 Casimersen [1] 113
23 IL6 [29] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
24 IL6 [29] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D08976 Pomalidomide [6] 28, 34, 51, 85, 227, 331
25 IL6 [29] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D09669 Siltuximab [2] 28, 331
26 IL6 [29] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D10080 Sirukumab [2] 41, 46
27 ITGA4 [7] PI3K-Akt signaling pathway, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Hypertrophic cardiomyopathy D06590 Firategrast [1] 13
28 ITGA4 [7] PI3K-Akt signaling pathway, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Hypertrophic cardiomyopathy D06886 Natalizumab [6] 13, 15, 25, 46, 63, 96
29 ITGA4 [7] PI3K-Akt signaling pathway, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Hypertrophic cardiomyopathy D08083 Vedolizumab [3] 94, 96, 97
30 ITGA4 [7] PI3K-Akt signaling pathway, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Hypertrophic cardiomyopathy D10540 Abrilumab [2] 96, 97
31 ITGB7 [5] PI3K-Akt signaling pathway, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy D08083 Vedolizumab [3] 94, 96, 97
32 ITGB7 [5] PI3K-Akt signaling pathway, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy D09901 Etrolizumab [2] 96, 97
33 ITGB7 [5] PI3K-Akt signaling pathway, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy D10540 Abrilumab [2] 96, 97
34 MYH7 [3] Thyroid hormone signaling pathway, Hypertrophic cardiomyopathy, Viral myocarditis D12265 Mavacamten [1] 58
35 PRKAA1 [11] mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Tight junction, Thermogenesis, Insulin signaling pathway, Oxytocin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Hypertrophic cardiomyopathy D00944 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
36 PRKAA1 [11] mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Tight junction, Thermogenesis, Insulin signaling pathway, Oxytocin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Hypertrophic cardiomyopathy D04966 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
37 PRKAA2 [11] mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Tight junction, Thermogenesis, Insulin signaling pathway, Oxytocin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Hypertrophic cardiomyopathy D00944 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
38 PRKAA2 [11] mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Tight junction, Thermogenesis, Insulin signaling pathway, Oxytocin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Hypertrophic cardiomyopathy D04966 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
39 CACNA2D3 [3] MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
40 CACNA2D3 [3] MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy D02716 Pregabalin [5] 13, 36, 46, 70, 298
41 TGFB1 [18] MAPK signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy D09620 Fresolimumab [4] 51, 85, 222, 274
42 TGFB2 [15] MAPK signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy D09620 Fresolimumab [4] 51, 85, 222, 274
43 TGFB3 [12] MAPK signaling pathway, TGF-beta signaling pathway, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, Renal cell carcinoma, Pancreatic cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy D09620 Fresolimumab [4] 51, 85, 222, 274
44 TNF [38] MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D00742 Etanercept [17] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
45 TNF [38] MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D00754 Thalidomide [20] 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
46 TNF [38] MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
47 TNF [38] MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D02597 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271
48 TNF [38] MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D02598 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
49 TNF [38] MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D03441 Certolizumab pegol [8] 37, 46, 49, 96, 97, 107, 226, 271
50 TNF [38] MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D04358 Golimumab [8] 46, 56, 84, 96, 97, 107, 270, 271
51 TNF [38] MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D04687 Lenalidomide [8] 16, 26, 28, 34, 49, 284, 300, 331
52 TNF [38] MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D05393 Pegsunercept [1] 46
53 TNF [38] MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D08976 Pomalidomide [6] 28, 34, 51, 85, 227, 331
54 TNF [38] MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D09944 Ozoralizumab [1] 46
55 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine [1] 6
56 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine [2] 50, 81
57 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
58 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
59 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
60 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00617 Nicardipine [2] 70, 86
61 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00619 Verapamil [3] 96, 140, 167
62 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine [1] 67
63 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine [1] 90
64 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil [3] 96, 140, 167
65 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
66 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
67 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D05442 Perhexiline [2] 58, 272
68 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
69 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
70 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine [2] 70, 86
71 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline [2] 58, 272
72 CACNA1C [13] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine [1] 226
73 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine [1] 6
74 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine [2] 50, 81
75 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
76 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
77 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
78 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00617 Nicardipine [2] 70, 86
79 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00619 Verapamil [3] 96, 140, 167
80 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine [1] 67
81 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine [1] 90
82 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil [3] 96, 140, 167
83 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
84 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
85 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D05442 Perhexiline [2] 58, 272
86 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
87 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
88 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine [2] 70, 86
89 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline [2] 58, 272
90 CACNA1D [12] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine [1] 226
91 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine [1] 6
92 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine [2] 50, 81
93 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
94 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
95 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
96 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00617 Nicardipine [2] 70, 86
97 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00619 Verapamil [3] 96, 140, 167
98 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine [1] 67
99 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine [1] 90
100 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil [3] 96, 140, 167
101 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
102 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
103 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D05442 Perhexiline [2] 58, 272
104 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
105 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
106 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine [2] 70, 86
107 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline [2] 58, 272
108 CACNA1F [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine [1] 226
109 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine [1] 6
110 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine [2] 50, 81
111 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
112 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
113 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
114 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00617 Nicardipine [2] 70, 86
115 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00619 Verapamil [3] 96, 140, 167
116 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine [1] 67
117 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine [1] 90
118 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil [3] 96, 140, 167
119 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
120 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
121 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D05442 Perhexiline [2] 58, 272
122 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
123 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
124 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine [2] 70, 86
125 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline [2] 58, 272
126 CACNA1S [10] MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, Insulin secretion, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine [1] 226
127 CACNA2D1 [3] MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
128 CACNA2D1 [3] MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy D02716 Pregabalin [5] 13, 36, 46, 70, 298
129 CACNA2D1 [3] MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy D11203 Mirogabalin [1] 70
130 CACNA2D2 [3] MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
131 CACNA2D2 [3] MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy D02716 Pregabalin [5] 13, 36, 46, 70, 298
132 CACNA2D2 [3] MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy D11203 Mirogabalin [1] 70
133 CACNA2D4 [3] MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
134 CACNA2D4 [3] MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy D02716 Pregabalin [5] 13, 36, 46, 70, 298